Loading clinical trials...
Loading clinical trials...
MIROCALS is a phase II study of ld-IL-2 as a therapeutic agent for ALS. A randomized (1:1), placebo-controlled, double-blind, parallel group trial will be carried out to assess ld-IL-2 safety and clin...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Centre Hospitalier Universitaire de Nīmes
NCT05204017 · Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, and more
NCT07322003 · Amyotrophic Lateral Sclerosis
NCT07414212 · Amyotrophic Lateral Sclerosis
NCT07401121 · ALS (Amyotrophic Lateral Sclerosis)
NCT05104710 · Amyotrophic Lateral Sclerosis
CHRU de Lille - Hôpital Roger Salengro
Lille
CHU de Limoges - Hôpital Dupuytren
Limoges
HCL - Hôpital Neurologique P. Wertheimer
Lyon
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions